EUCTR2004-000492-33-LV进行中（未招募）不适用
Healing of patients suffering from gastroesophageal reflux esophagitisgrade C-D according to Los Angeles classification after treatment with pantoprazole-magnesium dihydrate 80 mg o.d. in comparison topantoprazole-sodium sesquihydrate 40 mg o.d. over 4 or 8 weeks
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 800
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Written informed consent by the patient for study participation, prior to protocol specific procedures
- •- Outpatients of at least 18 years of age
- •- Endoscopically confirmed gastroesophageal reflux esophagitis (LA grade C-D)
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Gastrointestinal diseases:
- •- Endoscopically confirmed gastroesophageal reflux esophagitis (LA grade A-B)
- •- Zollinger-Ellison syndrome or other gastric hypersecretory condition
- •- Previous acid-lowering surgery or other surgery of the esophagus and/or upper gastrointestinal tract (exception: polypectomy and cholecystectomy)
- •- On initial endoscopy, presence of obstructive esophageal strictures, Schatzki’s ring, esophageal diverticula, esophageal varices, achalasia or Barrett‘s esophagus with known high-grade dysplasia or longer than 3 cm
- •- Symptomatic GERD without any endoscopic findings
- •- Acute peptic ulcer and/or ulcer complications
- •- Pyloric stenosis
- •- Inflammatory bowel diseases
研究者
相似试验
进行中（未招募）
不适用
Healing of patients suffering from gastroesophageal reflux esophagitisgrade C-D according to Los Angeles classification after treatment with pantoprazole-magnesium dihydrate 80 mg o.d. in comparison topantoprazole-sodium sesquihydrate 40 mg o.d. over 4 or 8 weeks - Magnum IIGastroesophageal reflux esophagitisMedDRA version: 5.0Level: lltClassification code 10038263EUCTR2004-000492-33-LTALTANA Pharma AG800
进行中（未招募）
不适用
Healing of patients suffering from gastroesophageal reflux esophagitisgrade A-D according to Los Angeles classification after treatment with pantoprazole-magnesium dihydrate 80 mg o.d. in comparison topantoprazole-sodium sesquihydrate 40 mg o.d. over 4 or 8 weeksGastroesophageal reflux esophagitisMedDRA version: 5.0Level: lltClassification code 10038263EUCTR2004-000493-32-ATALTANA Pharma AG1,980
进行中（未招募）
不适用
Healing of patients suffering from gastroesophageal reflux esophagitisgrade C-D according to Los Angeles classification after treatment with pantoprazole-magnesium dihydrate 80 mg o.d. in comparison topantoprazole-sodium sesquihydrate 40 mg o.d. over 4 or 8 weeks - Magnum IIEUCTR2004-000492-33-HUALTANA Pharma AG800
进行中（未招募）
1 期
Healing of patients suffering from gastroesophageal reflux esophagitisgrade A-D according to Los Angeles classification after treatment with pantoprazole-magnesium dihydrate 80 mg o.d. in comparison topantoprazole-sodium sesquihydrate 40 mg o.d. over 4 or 8 weeksGastroesophageal reflux esophagitisMedDRA version: 5.0Level: lltClassification code 10038263EUCTR2004-000493-32-SKALTANA Pharma AG
进行中（未招募）
不适用
Healing of patients suffering from gastroesophageal reflux esophagitisgrade A-D according to Los Angeles classification after treatment with pantoprazole-magnesium dihydrate 80 mg o.d. in comparison topantoprazole-sodium sesquihydrate 40 mg o.d. over 4 or 8 weeks - MagneticGastroesophageal reflux esophagitisMedDRA version: 5.0Level: lltClassification code 10038263EUCTR2004-000493-32-CZALTANA Pharma AG1,980